Floatz logo

Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301)

DCIS

Integro Theranosticsprotein_peptidePhase 1/2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the DCIS cohort.

Asset / SponsorPhaseRating
ROPIVACAINE
Zealand University Hospital
Phase 4BB
SUFENTANYL
Zealand University Hospital
Phase 4BB
TAMOXIFEN
Northwestern University
Phase 3BB
(Z)-Endoxifen
Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Phase 2BB
TAMOXIFEN
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301) is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
invasive ductal breast carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
gastrointestinal stromal tumorDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →